Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Armstrong

Showing results (971-980 of 1,035) with videos related to

Pageof 104
Sort By:
Journal of the National Cancer Institute|February 10, 2016
Association of Interferon Regulatory Factor-4 Polymorphism rs12203592 With Divergent Melanoma PathwaysDavid C Gibbs, Irene Orlow, Jennifer I Bramson, et al.
Circulation. Cardiovascular Interventions|June 9, 2026
Technical Success of Fetal Aortic Valvuloplasty in Relation to Center Volumes: A Report From the International Fetal Cardiac Intervention RegistryManon Gijtenbeek, Shaine A Morris, Ulrike Herberg, et al.
Journal of the American College of Cardiology|January 7, 2022
Reintervention and Survival After Transcatheter Pulmonary Valve ReplacementDoff B McElhinney, Yulin Zhang, Daniel S Levi, et al.
International Journal of Cancer|September 22, 2010
Biologic markers of sun exposure and melanoma risk in women: pooled case-control analysisCatherine M Olsen, Michael S Zens, Adele C Green, et al.
Obstetrics and Gynecology|January 12, 2019
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian CarcinomaPeter G Rose, James J Java, Ritu Salani, et al.
The Lancet. Oncology|May 4, 2020
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trialJonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Cancer Medicine|September 22, 2021
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safetyAna Oaknin, Amit M Oza, Domenica Lorusso, et al.
Journal of Cardiovascular Computed Tomography|March 3, 2023
Appropriateness of cardiovascular computed tomography and magnetic resonance imaging in patients with conotruncal defectsSarah S Pickard, Aimee K Armstrong, Sowmya Balasubramanian, et al.
Gynecologic Oncology|February 9, 2023
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancerThomas J Herzog, Sandro Pignata, Sharad A Ghamande, et al.
Gynecologic Oncology|August 31, 2020
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinomaNicoletta Colombo, Amit M Oza, Domenica Lorusso, et al.
Pageof 104

Showing results (971-980 of 1,035) with videos related to

Sort By:
Pageof 104
Journal of the National Cancer Institute|February 10, 2016
Association of Interferon Regulatory Factor-4 Polymorphism rs12203592 With Divergent Melanoma PathwaysDavid C Gibbs, Irene Orlow, Jennifer I Bramson, et al.
Circulation. Cardiovascular Interventions|June 9, 2026
Technical Success of Fetal Aortic Valvuloplasty in Relation to Center Volumes: A Report From the International Fetal Cardiac Intervention RegistryManon Gijtenbeek, Shaine A Morris, Ulrike Herberg, et al.
Journal of the American College of Cardiology|January 7, 2022
Reintervention and Survival After Transcatheter Pulmonary Valve ReplacementDoff B McElhinney, Yulin Zhang, Daniel S Levi, et al.
International Journal of Cancer|September 22, 2010
Biologic markers of sun exposure and melanoma risk in women: pooled case-control analysisCatherine M Olsen, Michael S Zens, Adele C Green, et al.
Obstetrics and Gynecology|January 12, 2019
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian CarcinomaPeter G Rose, James J Java, Ritu Salani, et al.
The Lancet. Oncology|May 4, 2020
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trialJonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Cancer Medicine|September 22, 2021
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safetyAna Oaknin, Amit M Oza, Domenica Lorusso, et al.
Journal of Cardiovascular Computed Tomography|March 3, 2023
Appropriateness of cardiovascular computed tomography and magnetic resonance imaging in patients with conotruncal defectsSarah S Pickard, Aimee K Armstrong, Sowmya Balasubramanian, et al.
Gynecologic Oncology|February 9, 2023
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancerThomas J Herzog, Sandro Pignata, Sharad A Ghamande, et al.
Gynecologic Oncology|August 31, 2020
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinomaNicoletta Colombo, Amit M Oza, Domenica Lorusso, et al.
Pageof 104